Post-marketing surveillance shows canakinumab maintains effectiveness and safety in Japanese patients with systemic juvenile idiopathic arthritis, suggesting it is a reliable treatment option.
Canakinumab showed a favourable long-term safety profile and sustained effectiveness in Japanese patients with sJIA inadequately controlled by existing therapies. No new safety concerns emerged, and the safety profile was comparable to that observed in the earlier phase III study.
No takes yet. Share an insight, caveat, or question.
Akita et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: